PediaNotes

Approach to DSD in 2 year old

8 min read

Conceptual Framework & Epidemiology

  • Definition: DSD represents discrepancies among chromosomal, gonadal, and genital sex.
  • Prevalence: Approximately 1 in 4,000 infants born with DSD. Rises significantly if encompassing all variations (cryptorchidism, isolated hypospadias).
  • Pathophysiology: Disruption in meticulous choreography of endocrine, paracrine, and autocrine signaling pathways governing fetal gonadal development.
  • 2-Year-Old Context: Presentation at 2 years often delayed. Typical presentations include discovery of inguinal masses (testes in AIS or uterus in persistent Müllerian duct syndrome), progressive virilization in children raised as girls (5α-reductase deficiency or non-classic CAH), or investigation of syndromic developmental delays. HPG axis is physiologically dormant at this age (post-mini-puberty); basal gonadotropins and testosterone are uninformative, necessitating dynamic stimulation testing.

Classification & Molecular Etiology

DSD classification relies heavily on karyotype, dividing into three main categories.

46,XX DSD

Characterized by female karyotype with virilized external genitalia or ovotesticular development.

Etiology CategorySpecific Defect / GenePathophysiology & Clinical Features
Androgen Excess (CAH)CYP21A2 (21-Hydroxylase)Most common 46,XX DSD. Salt-wasting or simple virilizing. Elevated 17-OHP.
CYP11B1 (11β-Hydroxylase)Virilization with arterial hypertension. Elevated 11-deoxycortisol.
HSD3B2 (3β-HSD)Salt-wasting, mild virilization, elevated Δ5 steroids.
POR (P450 Oxidoreductase)Antley-Bixler syndrome (craniosynostosis, radiohumeral synostosis). Ambiguity in both sexes.
Maternal Androgen ExposurePlacental Aromatase DeficiencyMaternal virilization during pregnancy, fetal virilization.
Exogenous AndrogensProgestational drugs or maternal virilizing tumors.
Disorders of Gonadal DevelopmentSRY Translocation46,XX Testicular DSD (XX male). Translocation of SRY onto X chromosome. Testicular tissue present.
SOX9 Duplication / RSPO1Ovotesticular DSD or Testicular DSD. RSPO1 defect associated with palmoplantar hyperkeratosis.

46,XY DSD

Characterized by male karyotype with incomplete virilization, ambiguous, or female external genitalia.

Etiology CategorySpecific Defect / GenePathophysiology & Clinical Features
Disorders of Gonadal DevelopmentWT1Denys-Drash syndrome, WAGR syndrome. Dysgenetic testes, Wilms tumor, renal failure.
SF1 (NR5A1)Dysgenetic testes, primary adrenal failure, Müllerian structures absent.
SOX9Campomelic dysplasia (skeletal dysplasia, bowing of long bones).
SRY, DHH, ATRXComplete or partial gonadal dysgenesis (Swyer syndrome).
Disorders of Androgen SynthesisLHCGRLeydig cell hypoplasia. High LH, low testosterone.
SRD5A2 (5α-Reductase Type 2)Normal testosterone, low DHT. High T/DHT ratio (>17). Virilization occurs at puberty.
CYP17A1Hypertension, hypokalemia, sexual infantilism.
HSD17B317β-HSD type 3 deficiency. Low testosterone, high androstenedione.
Disorders of Androgen ActionAR (Androgen Receptor)Complete (CAIS) or Partial (PAIS). High LH, high testosterone. Female or ambiguous phenotype.

Sex Chromosomal DSD

KaryotypeClinical SyndromeFeatures
45,X/46,XYMixed Gonadal DysgenesisAsymmetrical gonads (streak gonad on one side, dysgenetic testis on other). Müllerian structures often present.
46,XX/46,XYChimerismOvotesticular DSD (True hermaphroditism). Both ovarian and testicular tissue present.

Clinical Evaluation

graph TD
    Start([2-Year-Old Child with Suspected DSD<br/>Ambiguous Genitalia]) --> Baseline

     Non-Palpable Pathway
    NonPalp[Non-Palpable Gonads] --> US1{Pelvic US: Uterus Present?}

     Non-Palpable 46, XY Pathway
    US1 -->|No: Typically 46,XY| XY1[Evaluate for Testicular Regression]
    XY1 --> AMH1[Check AMH & hCG Stim Test]
    AMH1 -->|Low AMH, Negative T Response| Vanish[Vanishing Testis Syndrome / Complete Gonadal Dysgenesis]

     46, XY Pathway
    US2 -->|No: Typically 46,XY| Tier2[Tier 2: Dynamic Endocrine Testing<br/>hCG Stimulation Test]
    Tier2 --> HCG{Testosterone Rise?}

    HCG -->|Normal Rise| NormalT[Evaluate Androgen Action/Conversion]
    NormalT --> Ratio{Check Hormone Ratios}
    Ratio -->|High T/DHT Ratio > 17| 5AR[5-alpha Reductase Type 2 Deficiency]
    Ratio -->|High Androstenedione/T Ratio| 17HSD[17-beta HSD Deficiency]
    Ratio -->|Normal Ratios, Undervirilized| AIS[Androgen Insensitivity Syndrome PAIS/CAIS]

    HCG -->|Poor/Absent Rise| LowT[Leydig Cell Aplasia / Synthesis Defect]
    LowT --> Dysgen[Testicular Dysgenesis / Biosynthetic Defect]

     Convergence to Tier 3
    SW --> Tier3
    SV --> Tier3
    11B --> Tier3
    XXOther --> Tier3
    Vanish --> Tier3
    5AR --> Tier3
    17HSD --> Tier3
    AIS --> Tier3
    Dysgen --> Tier3
    MGD --> Tier3
    OTD --> Tier3

    Tier3{Tier 3: Anatomical Delineation} --> Imaging[Advanced Imaging & Surgery<br/>Genitogram, MRI, Laparoscopy]
    Imaging --> MDT([Multidisciplinary Management<br/>Endocrinology, Urology, Genetics, Psychology])

    %% Styling Elements
    classDef testing fill:#f9f2f4,stroke:#d391a8,stroke-width:2px,color:#333;
    classDef diagnosis fill:#e2f0cb,stroke:#85b065,stroke-width:2px,color:#333;
    classDef intervention fill:#cce5ff,stroke:#66b2ff,stroke-width:2px,color:#333;

    class Baseline,US1,XX,OHP,Lytes,XY1,AMH1,US2,Tier2,HCG,NormalT,Ratio,LowT,SexChr,KaryoCheck,Tier3 testing;
    class CAH,SW,SV,11B,XXOther,Vanish,5AR,17HSD,AIS,Dysgen,MGD,OTD diagnosis;
    class Start,Imaging,MDT intervention;

Detailed Historical Assessment

  • Family History: Unexplained neonatal deaths (salt-wasting CAH), consanguinity (autosomal recessive disorders), infertility, delayed puberty.
  • Maternal History: Virilization during pregnancy (placental aromatase deficiency, maternal luteoma), ingestion of progestational/androgenic agents.
  • Infancy History: Neonatal salt-wasting crises (failure to thrive, recurrent vomiting, lethargy, polyuria) strongly implicate 21-OHD or 3β-HSD deficiency.
  • Pedigree Analysis: Amenorrheic aunts or partially virilized uncles suggest X-linked inheritance (e.g., Androgen Insensitivity Syndrome).

Physical Examination & Genital Assessment

  • General Examination: Assess for hyperpigmentation (ACTH excess in CAH), dehydration, or hypertension (11β-OHD, 17α-OHD).
  • Syndromic Stigmata:
    • Smith-Lemli-Opitz: 2-3 toe syndactyly, microcephaly, ptosis, cleft palate.
    • CHARGE Syndrome: Coloboma, heart defects, choanal atresia, ear anomalies.
    • Denys-Drash: Renal anomalies, Wilms tumor.
    • Campomelic Dysplasia: Bowed limbs, skeletal dysplasia.
  • Genital Anatomy:
    • Prader Staging: Grade I (clitoromegaly only) to Grade V (male-appearing genitalia with cryptorchidism).
    • Palpation of Gonads: Crucial step. Bilateral palpable gonads below the inguinal ring are almost always testes; virtually excludes 46,XX CAH. Absence of palpable gonads in a virilized child mandates ruling out CAH. Asymmetrical gonads suggest mixed gonadal dysgenesis or ovotesticular DSD.
    • Phallus/Urethra: Measure stretched penile length (micropenis <2.5 cm in neonate, <2 SD for age). Identify urethral meatus position (hypospadias) and presence of chordee.
    • Müllerian Structures: Confirm presence/absence via rectal examination or ultrasound.

Diagnostic Algorithms & Investigations

Tier 1: Baseline Biochemical & Genetic Profiling

  • Karyotype: Rapid blood karyotype (FISH/Microarray) is mandatory and dictates the diagnostic algorithm.
  • Serum 17-OHP: Essential to rule out 21-hydroxylase deficiency. Elevated in classic CAH.
  • Electrolytes & Blood Gas: Assess for hyponatremia, hyperkalemia, and metabolic acidosis (salt-wasting CAH) or hypokalemia (11β-OHD, 17α-OHD).
  • Anti-Müllerian Hormone (AMH): Assesses Sertoli cell function and presence of functioning testicular tissue. Low AMH with absent Müllerian structures indicates vanishing testis syndrome.

Tier 2: Dynamic Endocrine Testing (2-Year-Old Specifics)

  • Rationale: At 2 years of age, spontaneous HPG axis activity is suppressed. Basal LH, FSH, and testosterone levels are physiologically low and uninterpretable.
  • hCG Stimulation Test: Mandatory to assess Leydig cell capacity for testosterone synthesis.
    • Protocol: Administer hCG (e.g., 5,000 IU IM daily for 3 days).
    • Interpretations:
      • Normal testosterone rise: Excludes Leydig cell aplasia and major biosynthetic defects. Points towards AIS, 5α-reductase deficiency, or anatomical defects.
      • Absent/Poor testosterone rise: Indicates gonadal dysgenesis, vanished testes, or severe biosynthetic enzyme defect.
  • Testosterone/DHT Ratio: Measured post-hCG stimulation. Ratio >17 confirms 5α-reductase type 2 deficiency.
  • Androstenedione/Testosterone Ratio: Differentiates 17β-HSD3 deficiency.
  • GnRH Analogue Test: Evaluates pituitary gonadotropin reserve if central hypogonadism suspected, though less reliable in early childhood compared to mini-puberty or adolescence.

Tier 3: Anatomical Delineation

  • Pelvic Ultrasound: First-line imaging. Identifies Müllerian structures (uterus, upper vagina) and locates intra-abdominal gonads.
  • Genitogram: Contrast study to define internal ductal anatomy, level of vaginal fusion with urogenital sinus.
  • MRI/Laparoscopy: Resolves complex anatomical relationships or identifies dysgenetic gonads/streak gonads deep in the pelvis. Laparoscopy permits gonadal biopsy for histological diagnosis (e.g., differentiating ovotesticular DSD).

Multidisciplinary Management & Interventions

Collaborative Team & Psychological Counseling

  • Team Composition: Pediatric endocrinologist, pediatric urologist/surgeon, geneticist, neonatologist, and behavioral health professional (psychologist/psychiatrist).
  • Communication Protocol: Honest, sensitive communication. Avoid gender-specific pronouns prematurely (use “your baby”, “your child”). Avoid terms like “hermaphrodite”; utilize neutral terms like “gonads” and “phallus”.
  • Psychosocial Support: Address parental anxiety, guilt, and fears of social stigmatization. Provide connections to support groups (e.g., CARES foundation, AIS support groups).

Sex of Rearing Assignment

  • Best predictor of gender identity is sex of rearing, though exceptions exist.
  • Decision Factors: Potential for future sexual and reproductive function, anatomical status, surgical feasibility, and degree of prenatal brain androgenization.
  • 46,XX CAH: Reared as females. Excellent potential for fertility and sexual function with appropriate medical and surgical management.
  • 46,XY CAIS: Reared as females. Female gender identity is universal.
  • 46,XY PAIS: Sex assignment is challenging. Depends heavily on degree of virilization and penile response to exogenous testosterone.
  • 46,XY 5α-Reductase Deficiency: Virilization occurs at puberty. Many reared as females in childhood transition to male gender identity at puberty. Male rearing is often advised if diagnosed early.

Medical Therapy

  • CAH (21-OHD): Glucocorticoid replacement (Hydrocortisone 12-15 mg/m²/day in 3 divided doses) to suppress ACTH and adrenal androgens. Mineralocorticoid replacement (Fludrocortisone 0.05-0.1 mg/day) and sodium chloride supplementation for salt-wasting. Stress dosing required during illness.
  • Androgen Trial: In completely virilized genetic males (e.g., micropenis, PAIS reared as male), short course of testosterone (e.g., 25 mg testosterone enanthate IM monthly for 3 doses) assesses phallic growth potential and induces penile enlargement.

Surgical Considerations & Neoplasia Risk

  • Genitoplasty: Indications and timing remain controversial. Shared decision-making is paramount.
    • Females (CAH): Clitoroplasty and urogenital sinus repair. Early surgery (approx 1 year of age) favored by some centers to reduce urinary tract infections, while others advocate delaying vaginoplasty until puberty to prevent vaginal stenosis.
    • Males (Hypospadias/Chordee): Typically performed in stages during early childhood.
  • Gonadectomy: Indicated to prevent malignancy (gonadoblastoma, dysgerminoma) in dysgenetic gonads containing Y-chromosome material (e.g., 45,X/46,XY mixed gonadal dysgenesis, 46,XY complete gonadal dysgenesis).
    • In CAIS, gonadectomy is often deferred until post-puberty to allow spontaneous estrogen-induced feminization from testicular aromatization.

Long-Term Surveillance & Prognosis

  • Transition of Care: Structured transition to adult endocrinology and urology teams is essential for monitoring long-term hormonal replacement, bone health, and sexual function.
  • Fertility: Highly variable. Excellent in optimally managed 46,XX CAH. Rare in mixed gonadal dysgenesis or XX males. Assisted reproductive technologies (ART) increasingly utilized.
  • Psychosexual Outcome: Ongoing psychological evaluation required. Gender dysphoria may arise, requiring specialized psychological and medical support. Quality of life deeply dependent on early, honest disclosure and robust familial and medical support systems.

Backlinks

Graph View